Absci (NASDAQ:ABSI) and Geron (NASDAQ:GERN) Critical Comparison

Geron (NASDAQ:GERN) and Absci (NASDAQ:ABSI) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional & Insider Ownership

73.7% of Geron shares are owned by institutional investors. Comparatively, 52.0% of Absci shares are owned by institutional investors. 1.7% of Geron shares are owned by insiders. Comparatively, 10.5% of Absci shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Geron and Absci”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Geron	$204.56 million	3.04	-$83.50 million	($0.11)	-8.80
Absci	$1.56 million	1,306.07	-$115.18 million	($0.80)	-14.85

Geron has higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than Geron, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Geron has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Absci has a beta of 2.27, suggesting that its share price is 127% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Geron and Absci, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Geron	1	2	3	0	2.33
Absci	1	0	11	0	2.83

Geron currently has a consensus price target of $2.50, suggesting a potential upside of 158.13%. Absci has a consensus price target of $14.50, suggesting a potential upside of 22.05%. Given Geron’s higher probable upside, analysts plainly believe Geron is more favorable than Absci.

Profitability

This table compares Geron and Absci’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Geron	-34.17%	-24.48%	-10.30%
Absci	-7,756.38%	-61.71%	-54.52%

Summary

Geron beats Absci on 9 of the 14 factors compared between the two stocks.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.